Related Experiment Video
Updated: Jun 3, 2026
The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
Protective effects of MLIF analogs on cerebral ischemia-reperfusion injury in rats
1Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou 730000, PR China.
Abstract:
The monocyte locomotion inhibitory factor (MLIF) is an anti-inflammatory oligopeptide produced by Entamoeba histolytica. Among its different effects, it inhibits locomotion of human monocytes, hence its original name. The carboxyl-terminal end group Cys-Asn-Ser is the pharmacophore of anti-inflammatory peptide Met-Gln-Cys-Asn-Ser. In this study, the N-terminal of Cys-Asn-Ser was modified. With the aim to enhance the antioxidant ability and penetrability of Cys-Asn-Ser, we designed and synthesized two tetrapeptides Tyr-Cys-Asn-Ser and His-Cys-Asn-Ser. The neuroprotective effects of Tyr-Cys-Asn-Ser and His-Cys-Asn-Ser on focal ischemia reperfusion were investigated, and their pharmacological activities compared with Cys-Asn-Ser were studied. In order to study the mechanism of neuroprotective effect of these peptides, the level of oxidative stress markers malondialdehyde (MDA) and superoxide dismutase (SOD) and pro-inflammatory factors interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and myeloperoxidase (MPO) were detected in brain tissue homogenate.
Insights
Modified peptides Tyr-Cys-Asn-Ser and His-Cys-Asn-Ser show neuroprotective effects against focal ischemia reperfusion. These novel compounds demonstrate potential for treating brain injury by reducing oxidative stress and inflammation.
Area of Science:
- Biochemistry
- Neuroscience
- Pharmacology
Background:
- Monocyte Locomotion Inhibitory Factor (MLIF) is an anti-inflammatory oligopeptide.
- The Cys-Asn-Ser sequence is identified as the pharmacophore responsible for the anti-inflammatory activity.
- Enhancing antioxidant and penetrability properties of Cys-Asn-Ser is a therapeutic goal.
Purpose of the Study:
- To design and synthesize novel tetrapeptides Tyr-Cys-Asn-Ser and His-Cys-Asn-Ser.
- To investigate the neuroprotective effects of these modified peptides on focal ischemia reperfusion.
- To compare the pharmacological activities of the new peptides with the original Cys-Asn-Ser.
Main Methods:
- Synthesis of Tyr-Cys-Asn-Ser and His-Cys-Asn-Ser.
- Evaluation of neuroprotection in a focal ischemia reperfusion model.
- Measurement of oxidative stress markers (MDA, SOD) and pro-inflammatory factors (IL-1β, TNF-α, MPO) in brain tissue.
Main Results:
- Tyr-Cys-Asn-Ser and His-Cys-Asn-Ser demonstrated neuroprotective effects.
- The modified peptides modulated levels of oxidative stress and inflammatory markers.
- Pharmacological activities were compared, indicating potential therapeutic advantages.
Conclusions:
- The N-terminal modification of Cys-Asn-Ser enhances its potential neuroprotective capabilities.
- Tyr-Cys-Asn-Ser and His-Cys-Asn-Ser show promise as novel therapeutic agents for ischemic stroke.
- Further research is warranted to elucidate the precise mechanisms and optimize therapeutic application.
